… disease and heart failure are insulin resistant states associated with a high incidence of
diabetes. We assessed the effect of dapagliflozin … two complementary phase 3 studies, the DAPA-…

… This study aims to evaluate the impact of overlapping CRM conditions on clinical outcomes
… Ejection Fraction Heart Failure) trial, we examine whether the benefits of dapagliflozin may …

… -HF but we provide more granularity about the effect of dapagliflozin according to BMI, … study
were that an ‘obesity survival paradox’ persists in patients with HFrEF and that dapagliflozin …

… Importantly, this study demonstrated that dapagliflozin considerably increased the mean
KSSQ-TSS at 8 months in both patients with ischaemic and non-ischaemic aetiology. Moreover, …

… ), the mean daily dose was 49 mg, and 60.6% of patients were treated with between 20
and 40 mg at baseline, although the dose conversion calculation was different in this study. …

… With Heart Failure) trial comprised 2 randomized, placebo-controlled trials of heart failure—…
with HFpEF—which investigated the effects of dapagliflozin on KCCQ Total Symptom Score ([…

… • The DETERMINE clinical trials (Dapagliflozin Effect on … With Heart Failure) assessed the
effect of dapagliflozin on … the study drug occurred in 9 patients (5.8%) in the dapagliflozin …

… Study) trial (spironolactone vs placebo in severe heart failure with reduced ejection fraction
[HFrEF]), with its NNT of 9 to prevent a HF hospitalization and/or cardiovascular … dapagliflozin …

… , short-term, expenditure on disease management with delivering long-term projected health
… Thus, the objective of this study is to assess the cost-effectiveness of dapagliflozin added to …

… Among the full study population of 6263 participants in DELIVER, 589 (9.4%) were … of heart
failure in DARE-19. Data from DELIVER extend the available safety data of dapagliflozin with …